Skip to main content
. 2021 Feb 22;6(4):e142376. doi: 10.1172/jci.insight.142376

Table 2. Therapeutic administration of LLL12b during remitting phase suppresses EAE relapses in relapsing-remitting EAE model of MS.

graphic file with name jciinsight-6-142376-g122.jpg